The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib (Q46935674)

26 December 2017

title

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib (English)

1 reference

26 December 2017

author

Ahmed Mohammed Iqbal

6

1 reference

26 December 2017

author name string

Khorashad JS

1

1 reference

26 December 2017

Anand M

2

1 reference

26 December 2017

Marin D

3

1 reference

26 December 2017

Saunders S

4

1 reference

26 December 2017

Al-Jabary T

5

1 reference

26 December 2017

Margerison S

7

1 reference

26 December 2017

Melo JV

8

1 reference

26 December 2017

Goldman JM

9

1 reference

26 December 2017

Apperley JF

10

1 reference

26 December 2017

Kaeda J

11

1 reference

26 December 2017

publication date

1 April 2006

1 reference

26 December 2017

published in

Leukemia

1 reference

26 December 2017

volume

20

1 reference

26 December 2017

page(s)

658-663

1 reference

26 December 2017

issue

4

1 reference

26 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404137

exact match

0 references

cites work

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Pyrosequencing trade mark : A one-step method for high resolution HLA typing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

A sequencing method based on real-time pyrophosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

inferred from DOI database lookup

7 January 2021

based on heuristic

A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404137

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2404137

1 reference

26 December 2017

PubMed ID

16467863

1 reference

26 December 2017